SCHEMBL3066199

SCHEMBL3066199

CC(=O)N(Cc1ccc(N2CCN(C)CC2)nc1)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
DRD5 P21918 1/20 0.43
SLC6A9 P48067 1/20 0.42
SLC6A5 Q9Y345 1/20 0.42
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
RORC P51449 1/20 0.40
ACKR3 P25106 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AOC3 Q16853 3/20 0.39
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
PDE7A Q13946 1/20 0.39
HTR6 P50406 1/20 0.38
JAK1 P23458 1/20 0.38
SMO Q99835 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063852 0.87 SLC6A9 (0.41) DRD2DRD1DRD5SLC6A9SLC6A5
SCHEMBL3058310 0.86 HRH3 (0.40) DRD2DRD1DRD5SLC6A9SLC6A5
SCHEMBL3823818 0.85 AGER (0.48) DRD2SLC6A9SLC6A5RORCSMO
SCHEMBL8179598 0.84 HTR2A (0.57) SLC6A9SLC6A5ACKR3SMN1; SMN2RAB9A
SCHEMBL3860666 0.84 RORC (0.45) RORCSMN1; SMN2RAB9AL3MBTL1SMO
SCHEMBL3827281 0.83 AGER (0.54) SLC6A9SLC6A5SMN1; SMN2RAB9AL3MBTL1
SCHEMBL3824036 0.83 L3MBTL1 (0.55) RORCSMN1; SMN2RAB9AL3MBTL1SMO
SCHEMBL4739773 0.83 SLC6A9 (0.45) SLC6A9SLC6A5ACKR3L3MBTL1HTR6
SCHEMBL3827832 0.82 AGER (0.53) DRD2SLC6A9SLC6A5SMN1; SMN2RAB9A
SCHEMBL4737202 0.82 SLC6A9 (0.43) SLC6A9SLC6A5L3MBTL1HTR6SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US claimed
EP-2099754-A1 ION CHANNEL MODULATORS Wyeth a Corporation of the State of Delaware (US) 2009-09-16 EP claimed
WO-2008073929-A1 ION CHANNEL MODULATORS WYETH (US) 2008-06-19 WO claimed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267697-A1 ION CHANNEL MODULATORS CACNA1E, CACNA1A, CACNA1S DRD2 1271/4885DRD1 1298/4885DRD5 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.